ScholarIQanswers from OpenAlex & ORCID
Jonathan Strosberg
ResearcherPublications, citations & collaboration network
Jonathan Strosberg is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Jonathan Strosberg have?
ScholarIQindexed works
Jonathan Strosberg has 430 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Jonathan Strosberg have?
ScholarIQcitation count
Jonathan Strosberg has 21,892 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Jonathan Strosberg?
ScholarIQh-index
Jonathan Strosberg has an h-index of 70 in OpenAlex.
What is the i10-index of Jonathan Strosberg?
ScholarIQi10-index
Jonathan Strosberg has an i10-index of 196 in OpenAlex.
What is the ORCID of Jonathan Strosberg?
ScholarIQorcid
The ORCID for Jonathan Strosberg is on the source record.
What is the OpenAlex record for Jonathan Strosberg?
ScholarIQopenalex
The OpenAlex for Jonathan Strosberg is on the source record.
What are the most-cited papers on Jonathan Strosberg?
ScholarIQmost cited works
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin, Andrew Hendifar, James C. Yao, Beth Chasen, Erik Mittra, Pamela L. Kunz, Matthew H. Kulke, Heather A. Jacene, David Bushnell, Thomas M. O’Dorisio, Richard P. Baum, Harshad Kulkarni, Martyn Caplin, Rachida Lebtahi, Timothy J. Hobday, Ebrahim S. Delpassand, Eric Van Cutsem, Al B. Benson, Rajaventhan Srirajaskanthan, Marianne Pavel, Jaime Font de Mora, Jordan Berlin, Enrique Grande, Nicholas S. Reed, Ettore Seregni, Kjell Öberg, Maribel Lopera Sierra, Paola Santoro, Thomas Thevenet, Jack L. Erion, Philippe Ruszniewski, Dik J. Kwekkeboom, Eric P. Krenning
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
James C. Yao, Nicola Fazio, Simron Singh, Roberto Buzzoni, Carlo Carnaghi, Edward M. Wolin, Jiří Tomášek, Markus Raderer, Harald Lahner, Maurizio Voi, Lida Pacaud, Nicolas Rouyrre, Carolin Sachs, Juan W. Valle, Gianfranco Delle Fave, Eric Van Cutsem, Margot Tesselaar, Yasuhiro Shimada, Do‐Youn Oh, Jonathan Strosberg, Matthew H. Kulke, Marianne Pavel
First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas
Jonathan Strosberg, Robert L. Fine, Junsung Choi, Aejaz Nasir, Domenico Coppola, Dung‐Tsa Chen, James F. Helm, Larry K. Kvols
Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Manisha H. Shah, Whitney Goldner, Al B. Benson, Emily K. Bergsland, Lawrence S. Blaszkowsky, Pamela Brock, J.K.C. Chan, Satya Das, Paxton V. Dickson, Paul T. Fanta, Thomas J. Giordano, Þorvarður R. Hálfdánarson, Daniel M. Halperin, Jin He, Anthony P. Heaney, Martin J. Heslin, Fouad Kandeel, Arash Kardan, Sajid Khan, Boris W. Kuvshinoff, Christopher H. Lieu, Kimberly D. Miller, Venu G. Pillarisetty, Diane Reidy‐Lagunes, Sarimar Agosto Salgado, Shagufta Shaheen, Heloisa P. Soares, Michael C. Soulen, Jonathan Strosberg, Craig Sussman, Nikolaos A. Trikalinos, N. Uboha, Namrata Vijayvergia, Terence Z. Wong, Beth Lynn, Cindy Hochstetler
Gastroenteropancreatic Neuroendocrine Tumors
Mauro Cives, Jonathan Strosberg